IL175511A - Rosuvastatin degradation products - Google Patents

Rosuvastatin degradation products

Info

Publication number
IL175511A
IL175511A IL175511A IL17551106A IL175511A IL 175511 A IL175511 A IL 175511A IL 175511 A IL175511 A IL 175511A IL 17551106 A IL17551106 A IL 17551106A IL 175511 A IL175511 A IL 175511A
Authority
IL
Israel
Prior art keywords
rosuvastatin
lactone
degradation product
solution
acetonitrile
Prior art date
Application number
IL175511A
Other languages
English (en)
Other versions
IL175511A0 (en
Inventor
Nina Finkelstein
Original Assignee
Teva Pharma
Nina Finkelstein
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34676616&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL175511(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Teva Pharma, Nina Finkelstein filed Critical Teva Pharma
Publication of IL175511A0 publication Critical patent/IL175511A0/en
Publication of IL175511A publication Critical patent/IL175511A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/78—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
IL175511A 2003-12-02 2006-05-09 Rosuvastatin degradation products IL175511A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US52644903P 2003-12-02 2003-12-02
PCT/US2004/040329 WO2005056534A1 (en) 2003-12-02 2004-12-02 Reference standard for characterization of rosuvastatin

Publications (2)

Publication Number Publication Date
IL175511A0 IL175511A0 (en) 2006-09-05
IL175511A true IL175511A (en) 2011-11-30

Family

ID=34676616

Family Applications (1)

Application Number Title Priority Date Filing Date
IL175511A IL175511A (en) 2003-12-02 2006-05-09 Rosuvastatin degradation products

Country Status (13)

Country Link
US (6) US7244844B2 (US07692009-20100406-C00010.png)
EP (1) EP1689723B1 (US07692009-20100406-C00010.png)
JP (1) JP4733047B2 (US07692009-20100406-C00010.png)
KR (1) KR100887264B1 (US07692009-20100406-C00010.png)
CN (1) CN1894221B (US07692009-20100406-C00010.png)
AT (1) ATE507209T1 (US07692009-20100406-C00010.png)
CA (1) CA2546894C (US07692009-20100406-C00010.png)
DE (1) DE602004032465D1 (US07692009-20100406-C00010.png)
ES (1) ES2364143T3 (US07692009-20100406-C00010.png)
IL (1) IL175511A (US07692009-20100406-C00010.png)
PT (1) PT1689723E (US07692009-20100406-C00010.png)
TW (1) TWI351958B (US07692009-20100406-C00010.png)
WO (1) WO2005056534A1 (US07692009-20100406-C00010.png)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0218781D0 (en) 2002-08-13 2002-09-18 Astrazeneca Ab Chemical process
GB0312896D0 (en) 2003-06-05 2003-07-09 Astrazeneca Ab Chemical process
GB0324791D0 (en) 2003-10-24 2003-11-26 Astrazeneca Ab Chemical process
ATE507209T1 (de) * 2003-12-02 2011-05-15 Teva Pharma Referenzstandard zur charakterisierung von rosuvastatin
US7851624B2 (en) 2003-12-24 2010-12-14 Teva Pharamaceutical Industries Ltd. Triol form of rosuvastatin and synthesis of rosuvastatin
TWI353981B (en) 2005-02-22 2011-12-11 Teva Pharma Preparation of rosuvastatin
EP1968593B1 (en) * 2005-12-20 2017-08-23 LEK Pharmaceuticals d.d. Pharmaceutical composition comprising (e)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl-(3r,5s)-3,5-dihydroxyhept-6-enoic acid
MX2008014552A (es) * 2007-03-13 2009-03-09 Teva Pharma Forma de triol de rosuvastatina.
EP2189456A1 (en) * 2008-11-14 2010-05-26 LEK Pharmaceuticals d.d. New compounds prepared from omeprazole
JP5739820B2 (ja) 2008-12-30 2015-06-24 アークル インコーポレイテッド 置換５，６−ジヒドロ−６−フェニルベンゾ［ｆ］イソキノリン−２−アミン化合物
CN103454352B (zh) * 2013-07-30 2015-07-15 广东先强药业有限公司 一种hplc法测定瑞舒伐他汀钙的含量及其有关物质的方法
CN103776939A (zh) * 2014-02-11 2014-05-07 润泽制药(苏州)有限公司 瑞舒伐他汀钙制剂有关物质的制备检测方法
CN108398501A (zh) * 2018-03-02 2018-08-14 海南通用三洋药业有限公司 一种检测瑞舒伐他汀钙有关物质的方法
CN109020902B (zh) * 2018-07-23 2020-06-02 唯智医药科技（北京）有限公司 一种瑞舒伐他汀钙杂质及其制备方法与用途
CN114280181A (zh) * 2021-12-23 2022-04-05 浙江海翔川南药业有限公司 一种瑞舒伐他汀中间体及其有关物质的检测方法

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US37314A (en) * 1863-01-06 Improved composition for lemonade
US633198A (en) * 1899-02-08 1899-09-19 Wilhelm Magnus Hoekerstedt Automatic-lighting torch.
US4231938A (en) 1979-06-15 1980-11-04 Merck & Co., Inc. Hypocholesteremic fermentation products and process of preparation
US4444784A (en) 1980-08-05 1984-04-24 Merck & Co., Inc. Antihypercholesterolemic compounds
MX7065E (es) 1980-06-06 1987-04-10 Sankyo Co Un procedimiento microbiologico para preparar derivados de ml-236b
US4739073A (en) 1983-11-04 1988-04-19 Sandoz Pharmaceuticals Corp. Intermediates in the synthesis of indole analogs of mevalonolactone and derivatives thereof
NO177005C (no) 1988-01-20 1995-07-05 Bayer Ag Analogifremgangsmåte for fremstilling av substituerte pyridiner, samt mellomprodukter til bruk ved fremstillingen
US5177080A (en) 1990-12-14 1993-01-05 Bayer Aktiengesellschaft Substituted pyridyl-dihydroxy-heptenoic acid and its salts
WO1992022560A1 (en) * 1991-06-19 1992-12-23 Shionogi Seiyaku Kabushiki Kaisha Optically active intermediate and production thereof
JP2648897B2 (ja) * 1991-07-01 1997-09-03 塩野義製薬株式会社 ピリミジン誘導体
GB9626746D0 (en) 1996-12-23 1997-02-12 Knoll Ag Process
GB9812413D0 (en) 1998-06-10 1998-08-05 Glaxo Group Ltd Compound and its use
SI20070A (sl) 1998-09-18 2000-04-30 LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. Nove soli inhibitorjev HMG-CoA reduktaze
GB9903472D0 (en) 1999-02-17 1999-04-07 Zeneca Ltd Chemical process
GB0001621D0 (en) 2000-01-26 2000-03-15 Astrazeneca Ab Pharmaceutical compositions
GB0003305D0 (en) 2000-02-15 2000-04-05 Zeneca Ltd Pyrimidine derivatives
GB0028429D0 (en) 2000-11-22 2001-01-10 Astrazeneca Ab Therapy
SK1402004A3 (sk) 2001-08-16 2005-01-03 Teva Pharmaceutical Industries Ltd. Spôsob prípravy vápenatých solí statinov
KR20040026705A (ko) 2001-08-16 2004-03-31 테바 파마슈티컬 인더스트리즈 리미티드 스타틴의 칼슘 염 형태의 제조 방법
SE0103509D0 (sv) 2001-10-19 2001-10-19 Astrazeneca Ab Rosuvastatin in pre demented states
KR100511533B1 (ko) 2002-04-09 2005-08-31 임광민 키랄 중간체, 그의 제조방법 및 그를 이용한 HMG-CoA환원저해제의 제조방법
US20050222415A1 (en) 2002-05-21 2005-10-06 Yatendra Kumar Process for the preparation of rosuvastatin
GB0218781D0 (en) * 2002-08-13 2002-09-18 Astrazeneca Ab Chemical process
WO2004052867A1 (en) 2002-12-10 2004-06-24 Ranbaxy Laboratories Limited Process for the preparation of rosuvastatin
WO2005021511A1 (en) 2003-08-27 2005-03-10 Hetero Drugs Limited A novel process for amorphous rosuvastatin calcium
US20070191318A1 (en) * 2003-10-22 2007-08-16 Yatendra Kumar Process for the preparation of amorphous rosuvastatin calcium
CA2546701C (en) 2003-11-24 2010-07-27 Teva Pharmaceutical Industries Ltd. Crystalline ammonium salts of rosuvastatin
ATE507209T1 (de) * 2003-12-02 2011-05-15 Teva Pharma Referenzstandard zur charakterisierung von rosuvastatin
EP1797046A2 (en) 2004-09-27 2007-06-20 Ranbaxy Laboratories Limited Novel processes for preparing amorphous rosuvastatin calcium and a novel polymorphic form of rosuvastatin sodium
CA2594692A1 (en) 2005-01-31 2006-08-03 Ciba Specialty Chemicals Holding Inc. Crystalline forms of rosuvastatin calcium salt
WO2006100689A1 (en) 2005-03-22 2006-09-28 Unichem Laboratories Limited Process for preparation of rosuvastatin
WO2006106526A1 (en) 2005-04-04 2006-10-12 Unichem Laboratories Limited Process for preparation of calcium salt of rosuvastatin
EP2508514B1 (en) 2005-06-24 2017-10-18 LEK Pharmaceuticals d.d. Process for preparing amorphous rosuvastatin calcium free of impurities
WO2006136408A2 (en) 2005-06-24 2006-12-28 Lek Pharmaceuticals D.D. Process for preparing pure amorphous rosuvastatin calcium
GB0514078D0 (en) 2005-07-08 2005-08-17 Astrazeneca Uk Ltd Chemical process

Also Published As

Publication number Publication date
US20070249831A1 (en) 2007-10-25
ATE507209T1 (de) 2011-05-15
CN1894221A (zh) 2007-01-10
US20050187234A1 (en) 2005-08-25
US7692008B2 (en) 2010-04-06
IL175511A0 (en) 2006-09-05
EP1689723A1 (en) 2006-08-16
KR100887264B1 (ko) 2009-03-06
US7244844B2 (en) 2007-07-17
US20070244321A1 (en) 2007-10-18
US8487097B2 (en) 2013-07-16
CN1894221B (zh) 2012-08-08
CA2546894C (en) 2009-09-08
US20070255059A1 (en) 2007-11-01
EP1689723B1 (en) 2011-04-27
US20090188305A1 (en) 2009-07-30
CA2546894A1 (en) 2005-06-23
ES2364143T3 (es) 2011-08-25
JP4733047B2 (ja) 2011-07-27
US7741482B2 (en) 2010-06-22
US7692010B2 (en) 2010-04-06
US7692009B2 (en) 2010-04-06
JP2007512354A (ja) 2007-05-17
TW200522959A (en) 2005-07-16
DE602004032465D1 (de) 2011-06-09
WO2005056534A1 (en) 2005-06-23
TWI351958B (en) 2011-11-11
KR20060098396A (ko) 2006-09-18
US20070249830A1 (en) 2007-10-25
PT1689723E (pt) 2011-07-06

Similar Documents

Publication Publication Date Title
US7692010B2 (en) Reference standard for characterization of rosuvastatin
US7674923B2 (en) Process for preparing forms of atorvastatin calcium substantially free of impurities
US7884226B2 (en) Purification of rosuvatatin intermediate by thin film evaporation and chemical method
JP5330225B2 (ja) トリオール型ロスバスタチン
US7851624B2 (en) Triol form of rosuvastatin and synthesis of rosuvastatin
US20110112165A1 (en) Atorvastatin-aliskiren
Schneider et al. Determination of the new monoamine oxidase inhibitor brofaromine and its major metabolite in biological material by gas chromatography with electron-capture detection
Bertacche et al. Structural elucidation of an unknown Simvastatin by-product in industrial synthesis starting from Lovastatin
CN101631777A (zh) 罗苏伐他汀的三醇形式

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed
KB Patent renewed